Amylin Pharmaceuticals (AMLN) NewsBite - AMLN Downgraded By Stanford Research

Posted on Tuesday, August 19, 2008 2:38 PM

Amylin Pharmaceuticals (AMLN) was downgraded today by analysts at Stanford Research and the stock is now at $28.07, down $1.69 (-5.68%) on volume of 6,070,680 shares traded. AMLN was downgraded to Hold from Buy. Over the last 52 weeks the stock has ranged from a low of $23.75 to a high of $51.10. Amylin Pharmaceuticals stock has been showing support around $24.05 and resistance in the $37.85 range. Technical indicators for the stock are neutral and S&P gives AMLN a neutral 3 STARS (out of 5) hold ranking. If you are looking for a hedged play on AMLN the stock seems like it could be a candidate for an October out-of-the-money bear-call credit spread above the 35 range. [ABR-Seven Summits Strategic Investments NewsBite]

Stocks To Watch Today: MS, PBR, GM, F, MRK, BTU, NEM, BJ, PRU, UNP, TEVA, ACE (Click Symbol For Latest News)

Enter your email address below and Click on the [Sign Up] button to receive our exclusive daily Morning Market Update plus a FREE password for access to the news, insight and intelligence that can make a difference in the way you invest.

eMail Address:

del.icio.us

Portions of this content may be copywritten by Fresh Brewed Media, Wall Street Secrets Plus, Investors Observer, VHS, LLC., and RealTimeTraders.com. SmartReadMX and related technologies are covered by US Patent Office # 60/631,747.